🔗 Share this article

While the United States continues making sweeping revisions to its immunization schedules, one figure appears somewhat surprisingly: Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who first made her name by casting doubt on coronavirus shots in the pandemic and has focused upon potential fatalities following COVID-19 immunization in her recent time at the Food and Drug Administration.

Planned Overhauls to Childhood Immunization Program

Agency leaders had intended to reveal sweeping changes to the pediatric vaccination calendar earlier this month, aligning the US with the Danish vaccine program, sources say – a major change that would put the US out of step with many the world with no evidence for improved outcomes. The planned update has been delayed until the coming year.

Rather than the top vaccines chief, Høeg is listed to present at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this calendar year.

Consolidating Power at the FDA

This interim role may indicate a tighter collaboration between the drug and vaccine divisions as Dr. Høeg and Prasad consolidate power at the agency – and it suggests a greater focus upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for halting specific childhood shot schedules in the US to become more similar to Denmark's approach, a country with comprehensive healthcare and a population roughly the size of the state of Wisconsin.

To date statements, she has continued to focus on vaccines – usually the responsibility of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Concerns Over Background

Dr. Høeg has no obvious track record in drug development, oversight or leadership, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the FDA chief and CBER since March.

“She appears not to have the requisite experience” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in leading a sizeable institution. She is not an expert in industry regulation.”

Previous heads of CBER would “be deeply familiar with laws and regulations and the underlying principles of drug development”, said a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that prior appointees who ran CBER have had.”

CDER has an enormous workload at the agency, Woodcock pointed out.

“Many people just zeroes in on the innovative therapies, but the off-patent medication office approves thousands of off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and other areas, and each of these need to be managed,” Dr. Woodcock explained. “The area you overlook, that is precisely what that I always told people is going to cause problems.”

Additionally, a significant leadership aspect to the job, which manages over 5,000 personnel. “It’s a enormous leadership role, if you do it right,” Woodcock added.

Agency Reaction and Disputed Initiatives

In response to concerns about Dr. Høeg's fitness for the role and whether this selection represents increased cooperation among FDA leaders on immunizations, a press secretary said that the “questions stem from flawed assumptions”.

“This background matches the duties of her position,” the official stated, noting the time Høeg spent advising the agency head on “medication safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the agency head's new fast-track approval initiative, a controversial rapid medication authorization process that allegedly concerned her preceding directors. “How are these drugs being selected for this voucher program? Who makes the choices?” Dr. Howard questioned. “There is a lot of lack of transparency going on at the regulatory body right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards less stringent regulations of all drugs, except for immunizations.”

Public Track Record on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if troubling, past, some experts have noted. She released a analysis using non-validated public submissions to assess the incidence of heart inflammation following Covid immunization. She advised the state of Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccines are pose a greater threat than they are.

Among her “policy goals” for the new administration featured altering guidelines for new vaccines and ending “optional” vaccines, she stated post-election on a online show. At the agency, Høeg has reportedly proposed excluding teenage boys from obtaining COVID-19 vaccinations.

“She is an all-around true believer who commences with her beliefs and works backwards to accommodate the science in a highly misleading, dishonest manner,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of other skeptics, {like|